Sage Therapeutics Stock News

Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.

Depending on who you ask, a recession is either right around the corner or the stock market is ready to rattle off a seismic bull run.

Sage Therapeutics Inc. shares dropped 17% early Wednesday after the company said its experimental treatment for mild cognitive impairment in patients with Parkinson's disease fell flat in a clinical t

Sage Therapeutics said on Wednesday it will stop development of its experimental drug to treat Parkinson's disease after it failed a mid-stage study, sending the company's shares down 4% before the be

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a l

Sage Therapeutics, Inc. (SAGE) reported earnings 30 days ago. What's next for the stock?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will

Sage Therapeutics' (SAGE) earnings and revenues surpass estimates in the fourth quarter of 2023. Focus on newly launched PPD drug, Zurzuvae.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a l

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will

Anyone who has dealt with a mental illness or has a loved one who struggles with a mental illness knows how devastating these diseases are. However, a growing number of biotechnology companies are giv

Sage Therapeutics (SAGE) reports dismal third-quarter results. It intends to price the recently approved oral postpartum depression pill Zurzuvae at $15,900 for an entire 14-day treatment course.

Third-quarter figures were not inspiring to investors. The biotech missed rather badly on both the top and bottom lines.

SAGE Therapeutics, Inc. (NASDAQ:SAGE ) Q3 2023 Earnings Conference Call November 7, 2022 8:00 AM ET Company Participants Ashley Kaplowitz - Director, IR Barry Greene - President, CEO & Director Christ

Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $2.81 per share versus the Zacks Consensus Estimate of a loss of $2.64. This compares to loss of $2.31 per share a year ago.